GRAL News and Press, GRAIL Inc.

2026-03-11 07:20:00 ET Shares in the MCED test company Grail (NASDAQ: GRAL) declined by 45.6% in February, according to data from S&P Global Market Intelligence . There's little doubt about the cause of the crash. The healthcare company released disappointing top-l...

GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES PR Newswire Grail told investors cash burn would be no more than $290 million while guidin...

GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire MENLO PARK, Calif. , March 2, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted...

2026-02-26 09:01:40 ET More on mid-cap stocks MDY: A Primer On The Oldest Mid-Cap ETF SPS Commerce, Inc. 2025 Q4 - Results - Earnings Call Presentation SPS Commerce, Inc. (SPSC) Q4 2025 Earnings Call Transcript Top Quant rated mid cap stocks with negative EPS...

GRAIL to Present at the TD Cowen 46th Annual Health Care Conference PR Newswire MENLO PARK, Calif. , Feb. 24, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company mana...

New York, New York--(Newsfile Corp. - February 24, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into GRAIL, Inc. ("GRAIL, Inc.") (NASDAQ: GRAL) concerning potential violations of the federal securities laws. On the Q3 2025 earnings call on November 12, 2...

2026-02-24 14:13:58 ET Grail (NASDAQ: GRAL) stock rose by more than 16% by midday. The move follows a couple of days of brutal declines after the release of top-line results from its three-year, 142,000-person trial of its Galleri multi-cancer early detection (MCED) test with Engl...

2026-02-24 11:05:00 ET There’s been a lot of talk in recent years about “liquid biopsies” and especially about the promise of using blood samples to test for a wide variety of cancers at once. In most cases, this involves looking for fragments of tumor-associate...

GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Investors and Potential Witnesses to Contact Law Firm GRAL INVESTIGATION NOTICE: Robbins Geller Rudman & Dowd LLP Launches Investigation into GRAIL, Inc., Encourages Inv...

2026-02-23 16:15:00 ET Shares of cancer-detection firm Grail (NASDAQ: GRAL) fell by half in last Friday's trading session. That's quite a turnabout after the company's share price more than quintupled in 2025, from about $19 a share in January to $110 in November. Last week shar...